Equashield

Company Overview

Snapshot

Founded in April 2009 by Erik Shem Tov and Marino Kriheli, Equashield operates with 51–200 employees. The company was acquired by Nordic Capital in October 2022.

Business overview

Equashield Medical develops advanced, automated solutions designed to protect healthcare workers and facilities from hazardous drug exposure and contamination. The company's core products include Equashield CSTD, an airtight closed-system drug-transfer device, and Equashield Pro, an automatic compounding system utilizing image-processing algorithms for process monitoring and control. Equashield serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically focusing on medical devices and medical treatment and therapeutics.

Strategic signal

In October 2022, Equashield sold a 25% stake to Nordic Capital, valuing the company at $1.3 billion. This acquisition signals strong investor confidence in Equashield's market position and its patented technologies for hazardous drug handling, indicating a significant strategic validation and potential for further expansion within the medical devices sector.

Company Intelligence Q&A

What is Equashield's primary focus?

Equashield focuses on providing advanced, automated solutions to protect healthcare workers and facilities from the risks associated with hazardous drug exposure and contamination.

When was Equashield acquired?

Equashield was acquired by Nordic Capital in October 2022.

What is the Equashield CSTD?

The Equashield CSTD is an airtight closed-system drug-transfer device designed to protect against occupational exposure to hazardous drugs.

What is the purpose of Equashield Pro?

Equashield Pro is an automatic compounding system specifically designed to handle multiple tasks simultaneously, using advanced proprietary image-processing algorithms to monitor and control all stages of the drug preparation process.

What was the valuation of Equashield during its acquisition by Nordic Capital?

In October 2022, Equashield was valued at $1.3 billion when Nordic Capital acquired a 25% stake in the company.